Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
Biostrata Ltd on behalf of Thermo
RANDOX LABORATORIES

New Genetic Test for Breast Cancer Launched

By Labmedica International staff writers
Posted on 17 Dec 2013
Image: BRCAvantage collection kit (Photo courtesy of Quest Diagnostics).
Image: BRCAvantage collection kit (Photo courtesy of Quest Diagnostics).
A cutting-edge test that identifies mutations in breast cancer genes (BRCA1 and BRCA2) that are associated with increased risk of inherited breast and ovarian cancers has been launched.

A woman with a confirmed BRCA1 or BRCA2 gene mutations is at greater risk of developing cancer during her lifetime with up to an 85% risk of breast cancer and up to a 40% risk of ovarian cancer compared to the general population.

The assay is called BRCAvantage and comprises four individual tests that are administered on the basis of a patient’s risk level. The test screens for known harmful BRCA 1/2 mutations using next generation sequencing and multiplex ligation-dependent probe amplification (MLPA). Identified gene variants are cross-referenced with mutational databases for clinical analysis. To facilitate the implementation of BRCAvantage, the production company, Quest Diagnostics (Madison, NJ, USA), announced that it will offer clinicians and patients access to third-party genetic counselors.

BRCA1 and BRCA2 are genes with known mutations responsible for increasing the risk of hereditary breast and ovarian cancer and associated cancers in women, and for prostate and breast cancer among men. Genetic testing is recommended for people with an immediate family member diagnosed with breast cancer at age 45 or younger; a personal history of breast cancer at age 45 or younger; a family member diagnosed with ovarian cancer at any age; a personal or family history of both breast and ovarian cancers on the same side of the family; a personal or family history of male breast cancer; Ashkenazi Jewish heritage, or a personal or family history of bilateral breast cancer.

Jon R. Cohen, MD, senior vice president and chief medical officer at Quest diagnostics said, “Quest stands for the power of knowing. Making sure patients have access to a genetic test with proven clinical value is essential. Patients need to understand their cancer risks in order to make the most informed and timeliest decisions about their health. While not every woman should get a BRCA test, Quest has a special opportunity to ensure every woman for whom BRCA testing is indicated can access this important technology.”

Related Links:

Quest Diagnostics



CELLAVISION AB
KARL HECHT GMBH & CO KG
77 ELEKTRONIKA

Channels

Hematology

view channel
Image: Plastic bag containing 0.5 to 0.7 liters of packed red blood cells in citrate, phosphate, dextrose, and adenine (CPDA) solution (Photo courtesy of Fresenius HemoCare).

Transfusion Protocols Compared After Cardiac Surgery

Unnecessary blood transfusions may increase healthcare costs both directly, because blood is an increasingly scarce and expensive resource, and indirectly due to the complications associated with transfusion.... Read more

Microbiology

view channel
Image:  Scanning electron micrograph of Pseudomonas aeruginosa from cultured biofilms in the respiratory tract of patients with cystic fibrosis (Photo courtesy of Science Photo Library).

New Method Tests for Cystic Fibrosis Infection Pathogens

A new method of testing the most common cause of life-threatening infection in people with cystic fibrosis could improve efforts to study and combat the illness. Cystic fibrosis is a serious genetic... Read more

Industry News

view channel

Latin America’s IVD Sector Exceeds USD 2 Billion, Brazil leads

The Latin American in vitro diagnostics (IVD) sector was estimated at USD 2.4 billion in 2014. Population growth, government insurance, newly insured patients, and updated healthcare facilities have driven growth in the region and will continue to propel demand, according to Kalorama Information (New York, NY, USA).... Read more
 

Events

06 Apr 2015 - 08 Apr 2015
07 Apr 2015 - 09 Apr 2015
13 Apr 2015 - 16 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.